Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors
- 1 January 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 109 (1), 168-180
- https://doi.org/10.1097/01.aog.0000249609.04831.7c
Abstract
To evaluate claims that elevated soluble fms-like tyrosine kinase-1 receptor (sFlt-1) and decreased placental growth factor predict preeclampsia. MEDLINE (1966–March 2006), EMBASE (1980–June 2006), POPLINE (1980–June 2006), CINAHL (1982–June 2006), and LILACS (1982–June 2006) were searched, and experts contacted. Studies identified and included were those reporting blood and urine levels of sFlt-1 or placental growth factor obtained before gestational week 30 or overt preeclampsia. Ten of 184 available studies analyzing sFlt-1 and 14 of 319 studies analyzing placental growth factor were included in this review. There was considerable interreport heterogeneity in methodology and results for sFlt-1 measured before gestational week 25. After week 25 placental growth factor and sFlt-1 levels varied consistently between the normal pregnancy group and women destined to develop preeclampsia, achieving significance in women who developed severe preeclampsia. Third-trimester increases in sFlt-1 and decreases in placental growth factor levels are associated with preeclampsia, specifically severe disease, based on retrospective data. The evidence is insufficient to recommend these markers to be used for screening, and prospective studies employing rigorous laboratory and study design criteria are needed to determine the clinical usefulness of these tests.Keywords
This publication has 27 references indexed in Scilit:
- Mapping the theories of preeclampsia: The need for systematic reviews of mechanisms of the diseaseAmerican Journal of Obstetrics and Gynecology, 2006
- Unraveling the mysteries of preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2005
- Mapping the Theories of Preeclampsia: The Role of HomocysteineObstetrics & Gynecology, 2005
- Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsiaThe Journal of Maternal-Fetal & Neonatal Medicine, 2005
- World Health Organization Systematic Review of Screening Tests for PreeclampsiaObstetrics & Gynecology, 2004
- Abnormal placentation and the syndrome of preeclampsiaSeminars in Nephrology, 2004
- Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insightsSeminars in Nephrology, 2004
- Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological ConsequencesJournal of Clinical Endocrinology & Metabolism, 2003
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJCI Insight, 2003
- Incidence and predictors of severe obstetric morbidity: case-control study Commentary: Obstetric morbidity data and the need to evaluate thromboembolic diseaseBMJ, 2001